Opthea (ASX:OPT) said its combination therapy candidate for diabetic macular edema showed potential in a first-in-human phase 1b study, according to a Tuesday filing with the Australian bourse.
The study tested the combination of sozinibercept and aflibercept in nine patients, with safety as the primary endpoint and mean change from baseline in best-corrected visual acuity as one of the secondary endpoints, the filing said.
Based on the results, the therapy was well tolerated, with no dose-limiting toxicities, the filing said. In addition, the 2 mg sozinibercept combination arm showed the highest best-corrected visual acuity gain.
Results from the study were published in the peer-reviewed journal Translational Vision Science & Technology, per the filing.
The company's shares rose past 5% in recent Tuesday trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.